Gary Schiller, MD, University of California, Los Angeles, Los Angeles, CA, describes an ongoing Phase Ib/II trial investigating the efficacy and safety of tagraxofusp with or without azacitidine in patients with acute myeloid leukemia (AML) with detectable measurable residual disease (MRD). Patients who achieve MRD negativity after one cycle will then receive allogeneic hematopoietic cell transplantation (alloHCT). No more than two cycles of the investigational treatment will be administrated in this trial. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.